These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 24595584)

  • 1. Novel skin brightener used as monotherapy for moderate melasma in skin of color.
    Grimes PE
    J Drugs Dermatol; 2014 Mar; 13(3):364-6. PubMed ID: 24595584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months.
    Bruce S
    J Drugs Dermatol; 2013 Mar; 12(3):S27-31. PubMed ID: 23545930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
    Kaufman BP; Alexis AF
    J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging.
    Serra M; Bohnert K; Narda M; Granger C; Sadick N
    J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Mehta RC; Garruto J; Gotz V; Sigler ML; Herndon JH
    J Drugs Dermatol; 2013 Mar; 12(3):s21-6. PubMed ID: 23545929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Herndon JH; Sigler ML; Gotz V; Garruto J; Mehta RC
    J Drugs Dermatol; 2012 Dec; 11(12):1478-82. PubMed ID: 23377519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of a superficial chemical peel combined with a multimodal, hydroquinone-free skin brightener using in vivo reflectance confocal microscopy.
    Goberdhan LT; Mehta RC; Aguilar C; Makino ET; Colvan L
    J Drugs Dermatol; 2013 Mar; 12(3):S38-41. PubMed ID: 23545932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigator-Blinded, Single-Center Study to Evaluate the Efficacy and Tolerability of a 4% Hydroquinone Skin Care System Plus 0.02% Tretinoin Cream in Mild-to-Moderate Melasma and Photodamage.
    Rendon M; Dryer L
    J Drugs Dermatol; 2016 Apr; 15(4):466-75. PubMed ID: 27050702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroquinone-free multimodal topical regimen for facial hyperpigmentation.
    Foad MS; Winters E
    J Drugs Dermatol; 2013 Mar; 12(3):S42-4. PubMed ID: 23545933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma.
    Tirado-Sánchez A; Santamaría-Román A; Ponce-Olivera RM
    Int J Dermatol; 2009 Aug; 48(8):893-5. PubMed ID: 19659872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pigmentation control in pregnancy-induced melasma: Clinical assessment of a non-hydroquinone, non-retinol pigment-correcting serum.
    Makino ET; Jiang LI; Stephens TJ; Mikati M; Mehta RC
    J Cosmet Dermatol; 2022 Nov; 21(11):5739-5746. PubMed ID: 35708506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating epidermal melasma with a 4% hydroquinone skin care system plus tretinoin cream 0.025%.
    Grimes P; Watson J
    Cutis; 2013 Jan; 91(1):47-54. PubMed ID: 23461059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma.
    Monheit GD; Dreher F
    J Drugs Dermatol; 2013 Mar; 12(3):270-4. PubMed ID: 23545908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma.
    Ramírez SP; Carvajal AC; Salazar JC; Arroyave G; Flórez AM; Echeverry HF
    J Drugs Dermatol; 2013 Jun; 12(6):e106-10. PubMed ID: 23839199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Evaluation of a 4% Hydroquinone + 1% Retinol Treatment Regimen for Improving Melasma and Photodamage in Fitzpatrick Skin Types III-VI.
    Rendon MI; Barkovic S
    J Drugs Dermatol; 2016 Nov; 15(11):1435-1441. PubMed ID: 28095558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system.
    Hantash BM; Jimenez F
    J Drugs Dermatol; 2012 May; 11(5):660-2. PubMed ID: 22527440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
    Taylor SC; Torok H; Jones T; Lowe N; Rich P; Tschen E; Menter A; Baumann L; Wieder JJ; Jarratt MM; Pariser D; Martin D; Weiss J; Shavin J; Ramirez N
    Cutis; 2003 Jul; 72(1):67-72. PubMed ID: 12889718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin-lightening effects of a new face care product in patients with melasma.
    Scherdin U; Bürger A; Bielfeldt S; Filbry A; Weber T; Schölermann A; Wigger-Alberti W; Rippke F; Wilhelm KP
    J Cosmet Dermatol; 2008 Mar; 7(1):68-75. PubMed ID: 18254815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma.
    Hantash BM; Jimenez F
    J Drugs Dermatol; 2009 Aug; 8(8):732-5. PubMed ID: 19663110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of hydroquinone-resistant melasma using topical methimazole.
    Malek J; Chedraoui A; Nikolic D; Barouti N; Ghosn S; Abbas O
    Dermatol Ther; 2013; 26(1):69-72. PubMed ID: 23384022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.